YOLFTbeta
Shanghai Labway Clinical Laboratory Co Ltd

Shanghai Labway Clinical Laboratory Co Ltd

301060 · SHE · Healthcare / Diagnostics & Research

9.73CNY-0.77 (-7.33%)

Price History

Full chart

Market Stats

Previous Close10.50
Open10.00
Day Range9.70 – 10.45
52-Week Range7.86 – 14.25
Volume21.38M
Market Cap4.81B
P/E (TTM)133.56
Forward P/E0.00
EPS0.09
Dividend Yield1.50%
Beta0.54
50-Day Avg10.53
200-Day Avg10.22

About

Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, in-vitro diagnostic products, precision medicine, research and technical services, medical data management solutions and professional technical support services. In addition, the company offers leasing, business, and human resources services. The company serves medical and research institutes. Shanghai Labway Clinical Laboratory Co., Ltd. was founded in 1993 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Weixiong Zeng
  • Employees1.25K
  • HeadquartersBuilding 1, Lane 268, Shanghai, China, 200335, China
  • Websitehttps://www.labway.cn

Leadership

  • Mr. Weixiong ZengChairman & GM · b. 1968
  • Ms. Haiyang WangHead of Finance Center & Director · b. 1975
  • Mr. Zhisen MaoDeputy General Manager · b. 1960
  • Mr. Guowei FangDeputy GM & Head of Medical Center · b. 1956
  • Jun HeAccounting Supervisor
  • Ms. Crystal YangBoard Secretary · b. 1989

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue462.69M541.04M608.47M804.65M923.24M1.05B1.15B1.24B1.78B4.20B1.67B1.74B1.45B
Growth (%)-+16.93%+12.46%+32.24%+14.74%+14.03%+9.57%+7.34%+43.62%+136.14%-60.13%+4.05%-16.88%
Cost of Revenue289.96M373.54M394.95M534.72M648.22M731.98M806.98M842.97M1.11B2.42B1.35B1.41B1.10B
Gross Profit172.74M167.49M213.52M269.93M275.01M320.75M346.52M395.22M672.90M1.78B329.31M332.53M346.98M
Gross Margin37.33%30.96%35.09%33.55%29.79%30.47%30.04%31.92%37.84%42.37%19.67%19.09%23.96%
Operating Expense61.86M79.63M109.73M188.79M267.87M214.07M215.96M216.76M353.95M830.04M465.14M401.83M317.42M
Operating Income110.88M87.87M103.79M81.14M7.14M106.68M130.56M178.47M318.95M949.28M-135.82M-69.31M29.56M
Operating Margin23.96%16.24%17.06%10.08%0.77%10.13%11.32%14.41%17.94%22.61%-8.11%-3.98%2.04%
EBITDA117.48M101.36M122.04M106.68M28.02M164.32M177.44M206.40M366.73M977.23M-95.57M-32.17M96.18M
EBITDA Margin25.39%18.73%20.06%13.26%3.03%15.61%15.38%16.67%20.62%23.27%-5.71%-1.85%6.64%
Net Income84.34M70.34M82.31M58.76M6.42M73.39M92.24M110.38M203.84M617.32M-141.59M-109.44M-30.75M
Net Income Margin18.23%13.00%13.53%7.30%0.70%6.97%8.00%8.91%11.46%14.70%-8.46%-6.28%-2.12%
R&D3.14M2.99M--13.84M16.89M18.80M21.80M39.44M109.40M48.86M59.97M41.05M
R&D as % of Total Revenue0.68%0.55%--1.50%1.60%1.63%1.76%2.22%2.61%2.92%3.44%2.84%
Interest Expense1.04M6.85M--4.32M4.39M1.35M401.39K3.88M10.58M8.46M11.01M6.41M
Interest Expense % of Total Revenue0.23%1.27%--0.47%0.42%0.12%0.03%0.22%0.25%0.51%0.63%0.44%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets329.33M463.27M565.75M943.94M1.33B1.44B1.40B1.47B2.11B3.75B2.99B2.62B2.29B
Total Liabilities198.54M262.14M260.50M329.25M225.66M262.15M185.89M224.13M465.67M1.47B1.01B803.00M647.39M
Total Equity130.79M201.13M302.47M578.65M1.08B1.15B1.18B1.22B1.56B2.06B1.78B1.66B1.55B
Cash52.15M36.76M55.42M239.95M139.95M205.20M257.66M412.08M351.96M665.81M861.20M828.95M759.50M
Total Debt25.00M20.00M26.28M75.28M70.00M30.00M-68.49M65.70M211.86M348.70M247.07M-
Net Debt-27.15M-16.76M-29.14M-164.67M-69.95M-175.20M-257.66M-343.59M-286.26M-453.95M-486.58M-581.88M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.63M-82.77M79.70M27.14M-95.52M184.79M70.60M167.87M223.51M84.17M546.99M216.31M268.85M
Investing Cash Flow-21.54M-14.91M-44.34M-136.14M-428.53M-83.63M77.49M83.72M-403.41M180.05M-398.50M-68.58M-
Financing Cash Flow57.80M82.28M-16.69M286.56M432.03M-35.30M-96.41M-96.11M119.75M50.48M44.73M-180.25M-
Capital Expenditure16.13M14.91M42.45M103.24M130.61M73.34M39.51M44.55M118.88M230.08M398.89M76.62M58.49M
Free Cash Flow-14.50M-97.68M37.25M-76.11M-226.13M111.45M31.09M123.33M104.63M-145.91M148.10M139.70M210.36M
Dividends Paid1.04M6.85M9.60M9.53M27.82M3.47M64.42M35.25M302.42K125.61M136.71M7.36M92.70M
FCF to OCF-889.52%118.01%46.74%-280.48%236.73%60.31%44.03%73.46%46.81%-173.36%27.08%64.58%78.24%
Dividend Paid to FCF-7.20%-7.01%25.78%-12.52%-12.30%3.12%207.20%28.58%0.29%-86.09%92.31%5.27%44.07%

Earnings

Report DateSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------
EPS Actual0.200.070.440.630.430.030.05-0.060.00-0.350.000.04-0.14-0.17-0.020.010.01-0.080.090.07
Surprise--------------------
Timing--------------------

Key Statistics & Ratios

Market Cap4.81B
Enterprise Value4.22B
Trailing P/E133.56
Forward P/E0.00
Price / Sales3.76
Price / Book3.14
EPS0.09
Book Value3.89
Revenue (TTM)1.28B
Gross Profit (TTM)340.75M
EBITDA143.17M
Profit Margin3.02%
Operating Margin11.89%
Return on Equity3.46%
Return on Assets2.30%
Shares Outstanding400.52M
Shares Float165.17M
Beta0.54
Dividend Yield1.50%
Dividend Rate0.18
Payout Ratio1.86%

Dividends

20261×
0.18Jun 8, 2026
20251×
0.20Jun 9, 2025
20231×
0.30Jun 20, 2023
20221×
0.30Apr 29, 2022